Related Experiment Video
Updated: May 17, 2025

Multi-Photon Time Lapse Imaging to Visualize Development in Real-time: Visualization of Migrating Neural Crest Cells in Zebrafish Embryos
Published on: August 9, 2017
Pelizaeus-Merzbacher Disease as a Cause of Early-Onset Developmental Delay: A Case Report
Michela Galea1, Miriana Cocker1, Doriette Soler1
1Paediatrics, Mater Dei Hospital, Msida, MLT.
Abstract:
Pelizaeus-Merzbacher disease (PMD) is a rare X-linked hypomyelinating leukodystrophy disorder caused by a mutation in the proteolipid protein 1 (PLP1) gene which is responsible for myelin formation in the central nervous system. We report a case of PMD in a male patient who initially presented with developmental delay at three months and was ultimately diagnosed at 10 years and 7 months of age. We aim to describe the initial presentation, clinical course of PMD and the investigations that aid in diagnosis so that future cases may be identified earlier. During the investigative workup of our patient, a deletion of exon 16 - an extremely rare heterozygous nucleotide variation, c.330C>T (p.D110D) - was identified, the pathogenicity of which has not been previously documented in the literature. In our report, we also aim to highlight the potential use of biotin in improving symptoms in such patients as there is currently no curative treatment available.
Insights
Pelizaeus-Merzbacher disease (PMD), a rare X-linked disorder affecting myelin formation, was diagnosed late in a male patient. This case highlights diagnostic challenges and the potential of biotin as a supportive therapy.
Area of Science:
- Neuroscience
- Genetics
- Biochemistry
Background:
- Pelizaeus-Merzbacher disease (PMD) is a rare, X-linked hypomyelinating leukodystrophy.
- It results from mutations in the proteolipid protein 1 (PLP1) gene, crucial for central nervous system myelin formation.
Observation:
- A male patient presented with developmental delay at three months, diagnosed with PMD at 10 years and 7 months.
- Investigations revealed a rare deletion of exon 16 (c.330C>T, p.D110D) in the PLP1 gene, with uncharacterized pathogenicity.
- The patient's clinical course and diagnostic investigations are detailed.
Findings:
- The study identifies a novel, extremely rare heterozygous nucleotide variation (c.330C>T, p.D110D) in the PLP1 gene associated with PMD.
- The pathogenicity of this specific variation has not been previously documented.
Implications:
- Early identification of PMD cases can be improved through understanding initial presentations and diagnostic workup.
- Biotin supplementation is explored as a potential symptomatic treatment for PMD, given the lack of curative options.
More Related Videos
08:22A Novel Strategy Combining Array-CGH, Whole-exome Sequencing and In Utero Electroporation in Rodents to Identify Causative Genes for Brain Malformations
Published on: December 1, 2017
07:50A Metadata Extraction Approach for Clinical Case Reports to Enable Advanced Understanding of Biomedical Concepts
Published on: September 20, 2018
Related Concept Videos
Inborn Errors of Metabolism
Genomic Imprinting and Inheritance
The expression of some genes depends on which parent passed the gene to the offspring, through a phenomenon known as...
Sex-linked Disorders
Autism Spectrum Disorder
These core symptoms manifest differently among individuals, ranging from mild to severe. The disorder's complexity extends beyond its clinical presentation, encompassing a diverse range of biological, cognitive, and sociocultural influences.
Psychosis: Pathophysiology of Schizophrenia and Other Psychotic Disorders
Researchers have identified genetic factors that increase susceptibility to schizophrenia, underscoring the intricate interplay between genetics and environment in disease development. At the core of schizophrenia's pathophysiology is excessive dopaminergic neurotransmission within...
Lysosomal Hydrolases